Author:
Santos-de-Araújo Aldair Darlan,Bassi-Dibai Daniela,Dourado Izadora Moraes,da Luz Goulart Cássia,Marinho Renan Shida,de Almeida Mantovani Jaqueline,de Souza Gabriela Silva,dos Santos Polliana Batista,Roscani Meliza Goi,Phillips Shane A.,Borghi-Silva Audrey
Abstract
Abstract
Background
Type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) present a decrease in functional capacity due to the intrinsic nature of both pathologies. It is not known about the potential impact of T2DM on functional capacity when assessed by 6-min step test (6MST) and its effect as a prognostic marker for fatal and non-fatal events in patients with CHF.
Objective
to evaluate the coexistence of T2DM and CHF in functional capacity through 6MST when compared to CHF non-T2DM, as well as to investigate the different cardiovascular responses to 6MST and the risk of mortality, decompensation of CHF and acute myocardial infarction (AMI) over 36 months.
Methods
This is a prospective cohort study with 36 months of follow-up in individuals with T2DM and CHF. All participants completed a clinical assessment, followed by pulmonary function testing, echocardiography, and 6MST. The 6MST was performed on a 20 cm high step and cardiovascular responses were collected: heart rate, systemic blood pressure, oxygen saturation, BORG dyspnea and fatigue. The risk of mortality, acute myocardial infarction and decompensation of CHF was evaluated.
Results
Eighty-six participants were included. The CHF-T2DM group had a significantly lower functional capacity than the CHF non-T2DM group (p < 0.05). Forced Expiratory Volume in one second (L), ejection fraction (%), gender and T2DM influence and are predictors of functional capacity (p < 0.05; adjusted R squared: 0.419). CHF-T2DM group presented a higher risk of mortality and acute myocardial infarction over the 36 months of follow-up (p < 0.05), but not to the risk of decompensation (p > 0.05).
Conclusion
T2DM negatively affects the functional performance of 6MST in patients with CHF. Gender, ejection fraction (%), FEV1 (L) and T2DM itself negatively influence exercise performance.
Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Elendu C, Amaechi DC, Elendu TC, Ashna M, Ross-Comptis J, Ansong SO, et al. Heart failure and diabetes: understanding the bidirectional relationship. Medicine (Baltimore). 2023;102:E34906.
2. Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2023;28:585.
3. Theofilis P, Oikonomou E, Tsioufis K, Tousoulis D. Diabetes mellitus and heart failure: epidemiology, pathophysiologic mechanisms, and the role of SGLT2 inhibitors. Life. 2023;13:497.
4. Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023;15:e43697.
5. Thomas MC. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev. 2016;12:249.